Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation

被引:5
作者
Luo, Yinhua [1 ]
Cui, Shengyu [2 ]
Zhang, Changjiang [2 ]
Huang, Rui [2 ]
Zhao, Jinbo [3 ]
Su, Ke [3 ]
Luo, Dan [3 ]
Li, Yuanhong [3 ]
机构
[1] Hubei Univ Med, Dept Cent Hosp Tujia & Miao Autonomous Prefecture, Shiyan, Peoples R China
[2] Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan, Peoples R China
[3] Hubei Univ Med, Cardiovasc Dis Ctr, Cent Hosp Tujia & Miao Autonomous Prefecture, Wuhan, Enshi Prefectur, Peoples R China
来源
INTERNATIONAL JOURNAL OF GENERAL MEDICINE | 2022年 / 15卷
基金
中国国家自然科学基金;
关键词
in-stent restenosis; ISR; percutaneous coronary intervention; PCI; remnant cholesterol; RC; drug-eluting stents; DES; least absolute shrinkage and selection operator; LASSO; PERCUTANEOUS CORONARY INTERVENTION; TRIGLYCERIDE-RICH LIPOPROTEINS; CARDIOVASCULAR-DISEASE; LDL CHOLESTEROL; PREDICTORS; MANAGEMENT; GUIDELINE; MORTALITY; RISK;
D O I
10.2147/IJGM.S348148
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: In-stent restenosis (ISR) is regarded as a critical limiting factor in stenting for coronary heart disease (CHD). Recent research has shown that fasting residual cholesterol (RC) has been shown to have a substantial impact on coronary heart disease. Unfortunately, there have not been much data to bear out the relationship between RC and ISR. Then, the predictive value of RC for in-stent restenosis in patients with coronary heart disease was analyzed. Patients and Methods: Aiming to explore the relationship between RC and ISR, we designed a retrospective study of patients with CHD after drug-eluting stent (DES) implantation, combining the data from a public database and selecting the best-fitting model by comparing the optical subset with least absolute shrinkage and selection operator (LASSO) regression. Results: Analysis of the abovementioned two models showed that the optical subset optimal subset model, which was based on RC, creatine, history of diabetes, smoking, multi-vessel lesions (2 vessels or more lesions), peripheral vascular lesions (PAD), and blood uric acid, had a better fit (AUC = 0.68), and that RC was an independent risk factor for ISR in the abovementioned two models. Notwithstanding its limitation, this study does suggest that RC has good predictive value for ISR. Conclusion: Remnant cholesterol is an independent risk factor for in-stent restenosis after percutaneous coronary intervention (PCI) and is a reliable predictor of ISR.
引用
收藏
页码:1733 / 1742
页数:10
相关论文
共 50 条
  • [21] Efficacy and safety of drug-eluting stent implantation for the treatment of in-stent restenosis occurring within bare-metal stent and drug-eluting stent
    Ge, Heng
    Zhang, Qing
    Zhou, Wei
    He, Qing
    Han, Zhi-hua
    He, Ben
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2010, 11 (08): : 553 - 560
  • [22] Efficacy and safety of drug-eluting stent implantation for the treatment of in-stent restenosis occurring within bare-metal stent and drug-eluting stent
    Heng Ge
    Qing Zhang
    Wei Zhou
    Qing He
    Zhi-hua Han
    Ben He
    Journal of Zhejiang University SCIENCE B, 2010, 11 : 553 - 560
  • [23] Incidence and predictors of recurrent restenosis following implantation of drug-eluting stents for in-stent restenosis
    Lee, Cheol Whan
    Park, Chang-Bum
    Kim, Young-Hak
    Hong, Myeong-Ki
    Kim, Jae-Joong
    Park, Seong-Wook
    Park, Seung-Jung
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2007, 69 (01) : 104 - 108
  • [24] Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion
    Tomoi, Yusuke
    Soga, Yoshimitsu
    Iida, Osamu
    Shiraki, Tatsuya
    Kobayashi, Yohei
    Hiramori, Seiichi
    Ando, Kenji
    JOURNAL OF ENDOVASCULAR THERAPY, 2016, 23 (03) : 461 - 467
  • [25] Outcomes With Combined Laser Atherectomy and Intravascular Brachytherapy in Recurrent Drug-Eluting Stent In-Stent Restenosis
    Megaly, Michael
    Glogoza, Matthew
    Xenogiannis, Iosif
    Vemmou, Evangelia
    Nikolakopoulos, Ilias
    Omer, Mohamed
    Willson, Laura
    Monyak, David J.
    Sullivan, Patsa
    Stanberry, Larissa
    Chavez, Ivan
    Mooney, Michael
    Traverse, Jay
    Wang, Yale
    Garcia, Santiago
    Poulose, Anil
    Burke, M. Nicholas
    Brilakis, Emmanouil S.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2021, 22 : 29 - 33
  • [26] Factors Associated with Coronary In-Stent Restenosis after Drug-Eluting Stent Implantation in Patients on Chronic Hemodialysis
    Sugita, Hiroshi
    Motohiro, Masayuki
    Morishita, Syun
    Tanaka, Masami
    Tsujimoto, Satoshi
    Shiojima, Ichiro
    BLOOD PURIFICATION, 2022, 51 (04) : 383 - 389
  • [27] In-stent Restenosis after Drug-eluting Stent Implantation in Rheumatoid Arthritis: Possible Protective Effect of Methotrexate
    Kwon, Oh Chan
    Oh, Ji Seon
    Kim, Yong-Gil
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (09) : 1336 - 1338
  • [28] Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents
    Kitoga, M.
    Pasquet, A.
    Preumont, V.
    Kefer, J.
    Hermans, M. -P.
    Vanoverschelde, J. -L.
    Buysschaert, M.
    DIABETES & METABOLISM, 2008, 34 (01) : 62 - 67
  • [29] Late-phase inflammatory response as a feature of in-stent restenosis after drug-eluting stent implantation
    Yoneda, Shuichi
    Abe, Shichiro
    Kanaya, Tomoaki
    Oda, Kazuhiko
    Nishino, Setsu
    Kageyama, Michiya
    Taguchi, Isao
    Masawa, Nobuhide
    Inoue, Teruo
    CORONARY ARTERY DISEASE, 2013, 24 (05) : 368 - 373
  • [30] Value of S100A12 in predicting in-stent restenosis in patients with coronary drug-eluting stent implantation
    Liang, Hengyi
    Cui, Yuqi
    Bu, Haoran
    Liu, Hang
    Yan, Pengcheng
    Cui, Lianqun
    Chen, Liming
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (01) : 211 - 218